ArticleFrontiers in oncology2024

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Susanne Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.